Vernaglia, Ross Co-Author U.S. Chapter within First Edition of The Healthcare Law Review
September 1, 2017
Foley attorneys Larry Vernaglia and Anna Ross co-authored a chapter within the The Healthcare Law Review’s first edition, which covers all aspects of the U.S. health care system. Each chapter within this health care review is an in-depth synopsis of a different country’s health care economy and legal framework, and the publication as a whole gives readers an insight to the commonalities and differences between these international jurisdictions.
Within the U.S. chapter, Vernaglia and Ross included the following about the U.S. health care system:
- Changes the Affordable Care Act has brought to the U.S. and what its future looks like under the Trump administration
- The current health care economy
- The different types of available care
- Licensing of health care providers and professionals
- Negligence liability
- Ownership of health care businesses
- Health care commissioning and procurement
- Health care services marketing and promotion.
Read the U.S. chapter through the PDF below.
Author(s)
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.